About the Authors
- Sambasiva P. Rao
-
* E-mail: Sambasiva.rao@genzyme.com
Affiliation Neuroimmunology Research, Genzyme, A Sanofi Company, Framingham, Massachusetts, United States of America
- Jose Sancho
-
Affiliation Neuroimmunology Research, Genzyme, A Sanofi Company, Framingham, Massachusetts, United States of America
- Juanita Campos-Rivera
-
Affiliation Neuroimmunology Research, Genzyme, A Sanofi Company, Framingham, Massachusetts, United States of America
- Paula M. Boutin
-
Affiliation Neuroimmunology Research, Genzyme, A Sanofi Company, Framingham, Massachusetts, United States of America
- Peter B. Severy
-
Affiliation Neuroimmunology Research, Genzyme, A Sanofi Company, Framingham, Massachusetts, United States of America
- Timothy Weeden
-
Affiliation Immune Mediated Disease Biology Research, Genzyme, A Sanofi Company, Framingham, Massachusetts, United States of America
- Srinivas Shankara
-
Affiliation Neuroimmunology Research, Genzyme, A Sanofi Company, Framingham, Massachusetts, United States of America
- Bruce L. Roberts
-
Affiliations Neuroimmunology Research, Genzyme, A Sanofi Company, Framingham, Massachusetts, United States of America, Immune Mediated Disease Biology Research, Genzyme, A Sanofi Company, Framingham, Massachusetts, United States of America
- Johanne M. Kaplan
-
Affiliation Neuroimmunology Research, Genzyme, A Sanofi Company, Framingham, Massachusetts, United States of America
Competing Interests
All the authors are employees of Genzyme, from which they receive compensation. Alemtuzumab is in clinical development by Genzyme. This does not alter the authors' adherence to all the PLoS ONE policies on sharing the data and materials.
Author Contributions
Conceived and designed the experiments: SPR SS BR. Performed the experiments: SPR JS JCR PMB PBS TW. Analyzed the data: SPR. Contributed reagents/materials/analysis tools: SPR JS JCR PMB TW. Wrote the paper: SPR JK.